CEL-SCI Prices $2.5M Offering to Advance Cancer Immunotherapy Development CEL-SCI Corporation (NYSE American: CVM), a biotechnology company focused on cancer immunotherapy, has announced the pricing of a best-efforts public offering to raise approximately $2.56 million. The offering comprises 16,000,000 shares…
Egle Therapeutics Secures €9.3 Million in State Funding to Advance Treg-Targeting Immunotherapies Egle Therapeutics, a clinical-stage biotechnology company specializing in the development of immunotherapies targeting regulatory T cells (Tregs), has secured €9.3 million in state funding under the “Innovations in…
Forth Tx Debuts with Sofinnova’s Support to Transform Fibrosis Treatment Forth Therapeutics (Forth Tx), a biotechnology company pioneering next-generation precision therapeutics for fibrosis, officially launches today with significant backing from Sofinnova Partners, a leading European life sciences venture capital firm,…
BioClec Launches to Transform Alzheimer’s Treatment with Sofinnova’s Backing BioClec, a pioneering biotechnology company dedicated to revolutionizing treatments for Alzheimer’s disease, has officially launched. The company emerges from Biovelocita II, Sofinnova Partners’ €165 million biotech acceleration program, and is focused…
Sofinnova Partners’ Biotech Fund Exceeds Target at €165M Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm with offices in Paris, London, and Milan, has announced the final close of Sofinnova Biovelocita II. The fund exceeded its target,…
Protembis Forms Scientific Advisory Board of Leading Heart Experts Protembis, a privately-held cardiovascular medical device company, has announced the establishment of a Scientific Advisory Board (SAB) to provide strategic guidance and expert counsel on scientific and clinical matters. The SAB…
Edifecs Expands Risk Adjustment Capabilities with Point of Care Suspects Solution Edifecs, Inc., a global leader in health information technology solutions, has announced the launch of Point of Care Suspects, a new enhancement to its comprehensive Risk Adjustment offering. This…
OM1 Enters European Market to Enhance AI-Powered Real-World Evidence Solutions for Life Sciences OM1, a leader in real-world data (RWD) and AI-driven insights for the life sciences industry, has announced its expansion into Europe. This strategic move aims to strengthen…
ClearNote Health’s Avantect® Pancreatic Cancer Test Now Covered by Claritev’s National PPO Networks ClearNote Health, a company dedicated to advancing early detection of some of the deadliest cancers, has announced a significant agreement with Claritev, Inc. (NYSE: CTEV), formerly known…
LGM Pharma Expands U.S. Drug Manufacturing with $6M Investment in Advanced Dosage Capabilities LGM Pharma, a leading provider of tailored API and CDMO services across the entire drug product lifecycle, has announced a significant investment of over $6 million to…
PharmaCord and Mercalis Merge to Build Next-Gen Biopharma Platform PharmaCord and Mercalis, two leading providers of patient access and commercialization services for the biopharmaceutical industry, have announced a strategic merger to form one of the largest independent total solutions providers…
Signum Surgical Appoints Carol Burns as CEO to Lead Commercialization of BioHealx® Signum Surgical (‘Signum’ or ‘the Company’), a medical technology company developing innovative solutions for colorectal diseases, has announced the appointment of Ms. Carol Burns as Chief Executive Officer.…